Scalable production of gene therapy vectors: an interview with Frank Ubags

NewsGuard 100/100 Score
insights from industryFrank Ubags CEO, CEVEC Pharmaceuticals GmbH

Can you please give a brief overview of gene therapy? How successful has it been so far?

Gene therapy involves introducing genetic material into cells to replace missing or malfunctioning genes or to add a gene to express a beneficial protein in order to treat certain diseases, such as cancer or inherited disorders.

DNA double helix

Since the first gene therapy product was approved by regulatory authorities in the Western world in 2012, we are today in a good position for providing CAP®GT as the technology of choice for the commercials production of gene therapy vectors.

Almost 500 gene therapy candidates are currently in development. According to market reports, gene therapies targeting cancer alone could reach peak sales of $13 B by 2025.

No question that gene therapy is at the forefront of modern medical treatment. However, one of the biggest challenges in gene therapy today and still preventing this innovative approach from commercial use is the ability to reliably produce safe gene therapy vectors at an industrial scale. It is at this point that we are expecting to play a key role with our innovative CAP®GT technology by providing a platform that exactly addresses the market needs allowing industrial scale production of gene therapy viral vectors.

Why is the production of gene therapy vectors on an industrial scale so challenging?

A major challenge is caused by the nature of the traditionally used expression systems.

The major current production platforms for viral gene therapy vectors are adherently growing cells like human embryonic kidney (HEK) 293 cell lines which are used in cell biology research and the biotechnology industry to produce gene therapy vectors. However, the scalability of adherent cell culture is limited.

Moreover, these cultures often require serum for efficient cell growth, which is undesirable from a regulatory standpoint. Attempts at suspension cultures of HEK 293 are being made, but they often prove to be a technological hurdle.

Growing as pure single cells in serum-free suspension cultures, our CAP®GT cells provide the highest cell densities, allow for easier scale-up and reduced production costs when compared to adherent cell culture systems.

What factors must be taken into account when producing a vector that is both reliable and safe?

From my point of view there are three main factors:

  • A fully scalable system to produce flexible batch sizes from small scale to large industrial scale.
  • Chemically defined, serum free culture conditions.
  • A well-documented and safe expression host addressing all regulatory requirements.

Can you please outline CEVEC’s new unique cell-expression system for the scalable production of gene therapy vectors?

The CAP®GT cell lines, derived from a non-tumor human origin, were developed with complete documentation and full certification of materials. As from the start, the development was aimed at the industrial scale production of gene therapy vectors.

Growing in serum-free suspension cultures, CAP®GT cell lines provide high cell densities of up to 2x10e7/ml in all common bioreactor formats significantly outperforming HEK 293 cells and show very high transfection efficiencies with common transfection reagents and methods.

CAP®GT cell lines do not produce undesired replication competent adenovirus (RCA). This was a main objective as from start of the development program. Especially for the field of adenoviral vector production we outperform HEK 293 in this respect.

What viral species do CAP®GT cells support?

CAP®GT cells show a broad viral propagation spectrum relevant for gene therapy applications including lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).

In mid-September you announced a collaboration agreement in this with Généthon. Please can you outline CEVEC’s partnership with this company?

Généthon is an important player with huge experience in developing gene therapies for rare diseases with several products in clinical development. The fact that they have chosen our CAP®GT system for the production of lentiviral vectors for gene therapy applications is a strong endorsement of our technology.

Généthon plans to develop lentivirus packaging cell lines to address the field of rare diseases with its own portfolio of gene therapy products. Furthermore, Généthon will manufacture CAP®GT derived lentiviral vectors for its partners and customers. CEVEC will grant the corresponding license to Généthon’s partners for clinical trials and commercial production.

What further improvements can be made to CAP®GT technology?

We are currently working on so called packaging cell lines which would significantly facilitate the production process of gene therapy vectors, particularly in the lentiviral and AAV fields.

What do you think the future holds for the production of gene therapy vectors and how does CEVEC plan to contribute?

With the first products on the market and a huge pipeline of innovative products in clinical development, gene therapy is now well positioned to establish itself as a therapeutic option for a variety of diseases. The increasing number of available therapies and treatments will call for scalable industrial manufacturing of safe and efficient vectors including lentiviral, adenoviral and adeno-associated viral vectors on robust production platforms.

CEVEC’s CAP®GT expression platform is a fully scalable production system for gene therapy vectors with broad regulatory endorsement. The superior features in terms of easy scale up of the CAP®GT suspension cell lines, production efficiency of the expression system and safety of CAP®GT-derived viral vectors position the CAP®GT technology at the cutting-edge of the rapidly growing field of viral vector industrial scale manufacturing for gene therapy applications.

Where can readers find more information?

For more information, please visit our website under

About Frank Ubags, CEO of CEVEC Pharmaceuticals GmbHFrank Ubags

With over 35 years of leadership experience, Frank Ubags executed major financing and licensing transactions while instigating and driving company growth and turn around strategies. He initiated and executed several major M&A transactions in the Life Science sector, worldwide. Among others, he worked for Rhein Biotech, Kiadis Pharma and Scil Proteins in CEO, CFO and COO positions.

April Cashin-Garbutt

Written by

April Cashin-Garbutt

April graduated with a first-class honours degree in Natural Sciences from Pembroke College, University of Cambridge. During her time as Editor-in-Chief, News-Medical (2012-2017), she kickstarted the content production process and helped to grow the website readership to over 60 million visitors per year. Through interviewing global thought leaders in medicine and life sciences, including Nobel laureates, April developed a passion for neuroscience and now works at the Sainsbury Wellcome Centre for Neural Circuits and Behaviour, located within UCL.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cashin-Garbutt, April. (2018, August 23). Scalable production of gene therapy vectors: an interview with Frank Ubags. News-Medical. Retrieved on May 22, 2024 from

  • MLA

    Cashin-Garbutt, April. "Scalable production of gene therapy vectors: an interview with Frank Ubags". News-Medical. 22 May 2024. <>.

  • Chicago

    Cashin-Garbutt, April. "Scalable production of gene therapy vectors: an interview with Frank Ubags". News-Medical. (accessed May 22, 2024).

  • Harvard

    Cashin-Garbutt, April. 2018. Scalable production of gene therapy vectors: an interview with Frank Ubags. News-Medical, viewed 22 May 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New modular epigenome editing platform sheds light on gene regulation mechanisms